Diabetes Therapy
Exenatide reduced hemoglobin A1c and weight over 82 weeks in type 2 diabetics on metformin
Published in Obesity and Diabetes Week, July 24th, 2006
"The ability of the incretin mimetic exenatide to improve glycaemic control and reduce body weight was assessed over 82 weeks in patients with type 2 diabetes failing to achieve glycaemic control with maximally effective doses of metformin," scientists writing in the journal Diabetes Obesity & Metabolism report.
R.E. Ratner and colleagues working with Amylin Pharmaceutical explained, "In this interim 82-week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes & Obesity
Moxonidine improved glycemic control in hypertensive, overweight with metabolic syndrome symptoms - Diabetes Therapy
beta3 -Adrenergic activation improves diabetic state of nonobese diabetic MKR mice - Obesity Pathogenesis
GLP-1 shows diverse effects on glucose transport, lipolysis and lipogenesis in obese adipocytes - Obesity Pathogenesis
High portal free fatty acid causes hyperinsulinemia and may account for obesity complications - Obesity Pathogenesis
Uncoupling protein-3 prevents triglyceride build-up in adipose tissue and muscle - Awards
XLHealth specialist Mary L. Gardner named Maryland's Diabetes Educator of the Year - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
